Clinical and laboratory features of patients with SSc positive for IgG anti-survivin antibody. IgG anti-survivin antibody levels were determined by ELISA using human recombinant survivin. Optical density values greater than mean + 2 SD of healthy controls were considered positive.
| Characteristic | IgG Anti-survivin-positive, n = 25 | IgG Anti-survivin-negative, n = 36 |
|---|---|---|
| Female/male | 24/1 | 29/7 |
| Age at onset, mean ± SD yrs | 40 ± 16 | 47 ± 17 |
| Disease duration, mean ± SD yrs | 6.4 ± 8.2* | 4.9 ± 6.3 |
| Disease pattern, no. with diffuse/limited SSc | 13/12 | 24/12 |
| Clinical features | ||
| Modified Rodnan TSS, mean ± SD points | 13.6 ± 10.9 | 14.0 ± 10.9 |
| Pitting scars, % | 36 | 44 |
| Diffuse pigmentation, % | 52 | 55 |
| Contracture of phalanges, % | 40 | 50 |
| Organ involvement | ||
| Lung | ||
| Pulmonary fibrosis, % | 48 | 41 |
| VC, mean ± SD, % | 89 ± 26 | 94 ± 25 |
| DLCO, mean ± SD, % | 58 ± 17 | 58 ± 20 |
| Decreased VC, % | 36 | 33 |
| Decreased DLCO, % | 68 | 66 |
| Pulmonary hypertension, % | 4 | 18 |
| Esophagus, % | 60 | 55 |
| Heart, % | 12 | 13 |
| Kidney, % | 16 | 19 |
| Joint, % | 20 | 22 |
| Muscle, % | 24 | 19 |
| Laboratory findings | ||
| Positive for anti-topoisomerase I antibody, % | 56 | 41 |
| Positive for anti-centromere antibody, % | 36 | 33 |
| Serum IgG, mean ± SD mg/dl | 1712 ± 499 | 1641 ± 561 |
| ESR, mean ± SD mm/h | 17.0 ± 11.5 | 17.7 ± 14.1 |
| Serum survivin levels, mean ± SD pg/ml | 171 ± 53 | 181 ± 87 |
TSS: total skin thickness score; ESR: erythrocyte sedimentation rates; SSc: systemic sclerosis; VC: vital capacity; DLCO: diffusion capacity for carbon monoxide.
↵* p < 0.05 vs SSc patients without IgG anti-survivin antibody.